Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind placebo-controlled proof-of-concept study of KN203 in overactive bladder
2009-013334-24Phase 2Terminated
- Sponsor
- KeyNeurotek Pharmaceuticals
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KN203 in overactive bladder (OAB) and cystospasm (3 arms), sponsored by KeyNeurotek Pharmaceuticals. Primary endpoint: Change in frequency of micturition per 24 hours. Started Nov 2009; status: terminated.
02
Drugs
KN203
03
Conditions
overactive bladder (OAB)cystospasm
Beyond the preview
Go deeper on 2009-013334-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013334-24.